Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premedication to prevent carboplatin hypersensitivity in women with gynecological malignancy
ACTRN12613000646741Phase 2Not yet recruiting
- Sponsor
- The Royal Women's Hospital
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dexamethasone, loratadine and ranitidine in Gynecological neoplasia (2 arms), sponsored by The Royal Women's Hospital. Primary endpoint: Incidence of carboplatin hypersensitivity reactions. Planned start Jul 2013; status: not yet recruiting.
02
Drugs
dexamethasoneloratadineranitidine
03
Conditions
Gynecological neoplasia
Beyond the preview
Go deeper on ACTRN12613000646741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000646741.